November 4, 2016
Genfit gets FDA’s IND clearance for PBC drug to go on with phase 2 study
The primary objective is to determine the effect of daily oral administration of elafibranor on serum alkaline phosphatase (ALP) in these patients, based on relative change versus placebo.